

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 January 2022 (20.01.2022)



(10) International Publication Number
WO 2022/015922 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C12N 9/16 (2006.01)
C07K 14/725 (2006.01) G01N 33/574 (2006.01)
C07K 16/32 (2006.01)

(21) International Application Number:

PCT/US2021/041737

(22) International Filing Date:

15 July 2021 (15.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/052,502 16 July 2020 (16.07.2020) US

(71) Applicant: THE UNITED STATES OF AMERICA,
AS REPRESENTED BY THE SECRETARY, DE-
PARTMENT OF HEALTH AND HUMAN SERVICES
[US/US]; Office of Technology Transfer, National Insti-

tutes of Health, 6011 Executive Boulevard, Suite 325, MSC
7660, Bethesda, Maryland 20892-7660 (US).

(72) Inventors: LEVIN, Noam; 357 Congressional Lane,
Rockville, Maryland 20852 (US). LOWERY, III, Frank
J.; 13052 Martz Street, Clarksburg, Maryland 20871 (US).
PARKHURST, Maria R.; 4938 Grace Court, Ellicott City,
Maryland 21043 (US). ROSENBERG, Steven A.; 10104
Iron Gate Road, Potomac, Maryland 20854 (US).

(74) Agent: LAWLEY, Stephanie M. et al.; LEYDIG, VOIT
& MAYER, Two Prudential Plaza, Suite 4900, 180 North
Stetson Avenue, Chicago, Illinois 60601 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION




Fig. 1A

(57) Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine. The TCRs may recognize G12V RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))